Evaluation of placental growth factor and soluble Fms-like tyrosine kinase 1 as predictors of all-cause and cardiovascular mortality in patients with Type 1 diabetes with and without diabetic nephropathy

Diabetic Medicine

Volumn 29, Issue 3, 2012, Pages 337-344

  Theilade, S ^a   Lajer, M ^a   Jorsal, A ^a   Tarnow, L ^a   Parving, H H ^b,c   Rossing, P ^a  

^a STENO DIABETES CENTER   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Cardiovascular disease; Diabetic nephropathy; Placental growth factor; Soluble Fms like tyrosine kinase 1; Type1 diabetes

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; ANTIHYPERTENSIVE AGENT; C REACTIVE PROTEIN; CHOLESTEROL; CREATININE; HEMOGLOBIN A1C; PLACENTAL GROWTH FACTOR; VASCULOTROPIN RECEPTOR 1;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; FOLLOW UP; GENDER; GLOMERULUS FILTRATION RATE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; KIDNEY FUNCTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SMOKING; SYSTOLIC BLOOD PRESSURE;

ADULT; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; PREDICTIVE VALUE OF TESTS; PREGNANCY PROTEINS; PROSPECTIVE STUDIES; RISK FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84857342093     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2011.03482.x     Document Type: Article

References (30)

1. Alberti KG, Gray DP. The care of diabetes. Diabet Med 1998; 15: S3-S4.
2. Mombouli JV, Vanhoutte PM. Endothelial dysfunction: from physiology to therapy. J Mol Cell Cardiol 1999; 31: 61-74.
3. Astrup AS, Tarnow L, Pietraszek L, Schalkwijk CG, Stehouwer CD, Parving HH et al. Markers of endothelial dysfunction and inflammation in type1 diabetic patients with or without diabetic nephropathy followed for 10years: association with mortality and decline of glomerular filtration rate. Diabetes Care 2008; 31: 1170-1176.
4. Persson F, Rossing P, Hovind P, Stehouwer CD, Schalkwijk CG, Tarnow L et al. Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type2 Diabetes and Microalbuminuria (IRMA2) study. Scand J Clin Lab Invest 2008; 68: 731-738.
5. Mura M, dos Santos CC, Stewart D, Liu M. Vascular endothelial growth factor and related molecules in acute lung injury. J Appl Physiol 2004; 97: 1605-1617.
6. Pilarczyk K, Sattler KJ, Galili O, Versari D, Olson ML, Meyer FB et al. Placenta growth factor expression in human atherosclerotic carotid plaques is related to plaque destabilization. Atherosclerosis 2008; 196: 333-340.
7. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De MM et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001; 7: 575-583.
8. Hornig C, Weich HA. Soluble VEGF receptors. Angiogenesis 1999; 3: 33-39.
9. Nandy D, Mukhopadhyay D, Basu A. Both vascular endothelial growth factor and soluble Flt-1 are increased in type2 diabetes but not in impaired fasting glucose. J Investig Med 2010; 58: 804-806.
10. Cooper ME, Vranes D, Youssef S, Stacker SA, Cox AJ, Rizkalla B et al. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 1999; 48: 2229-2239.
11. Hohenstein B, Hausknecht B, Boehmer K, Riess R, Brekken RA, Hugo CP. Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man. Kidney Int 2006; 69: 1654-1661.
12. Kim NH, Oh JH, Seo JA, Lee KW, Kim SG, Choi KM et al. Vascular endothelial growth factor (VEGF) and soluble VEGF receptor FLT-1 in diabetic nephropathy. Kidney Int 2005; 67: 167-177.
13. Ku CH, White KE, Dei CA, Hayward A, Webster Z, Bilous R et al. Inducible overexpression of sFlt-1 in podocytes ameliorates glomerulopathy in diabetic mice. Diabetes 2008; 57: 2824-2833.
14. de Vriese AS, Tilton RG, Elger M, Stephan CC, Kriz W, Lameire NH. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 2001; 12: 993-1000.
15. Trepels T, Zeiher AM, Fichtlscherer S. The endothelium and inflammation. Endothelium 2006; 13: 423-429.
16. Lu YF, Lu SZ, Chen YD. Relationship between serum vasoactive factors and plaque morphology in patients with non-ST-segment elevated acute coronary syndrome. Chin Med J (Engl) 2010; 123: 193-197.
17. Hochholzer W, Reichlin T, Stelzig C, Hochholzer K, Meissner J, Breidthardt T et al. Impact of soluble fms-like tyrosine kinase-1 and placental growth factor serum levels for risk stratification and early diagnosis in patients with suspected acute myocardial infarction. Eur Heart J 2011; 32: 326-335.
18. Heeschen C, Dimmeler S, Fichtlscherer S, Hamm CW, Berger J, Simoons ML et al. Prognostic value of placental growth factor in patients with acute chest pain. J Am Med Assoc 2004; 291: 435-441.
19. Nakamura T, Funayama H, Kubo N, Yasu T, Kawakami M, Momomura S et al. Elevation of plasma placental growth factor in the patients with ischemic cardiomyopathy. Int J Cardiol 2009; 131: 186-191.
20. Di Marco GS, Reuter S, Hillebrand U, Amler S, Konig M, Larger E et al. The soluble VEGF receptor sFlt1 contributes to endothelial dysfunction in CKD. J Am Soc Nephrol 2009; 20: 2235-2245.
21. Roncal C, Buysschaert I, Chorianopoulos E, Georgiadou M, Meilhac O, Demol M et al. Beneficial effects of prolonged systemic administration of PlGF on late outcome of post-ischaemic myocardial performance. J Pathol 2008; 216: 236-244.
22. Tarnow L, Astrup AS, Parving HH. Elevated placental growth factor (PlGF) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. Scand J Clin Lab Invest Suppl 2005; 240: 73-79.
23. Tarnow L, Groop PH, Hadjadj S, Kazeem G, Cambien F, Marre M et al. European rational approach for the genetics of diabetic complications-EURAGEDIC: patient populations and strategy. Nephrol Dial Transplant 2008; 23: 161-168.
24. Iwama H, Uemura S, Naya N, Imagawa K, Takemoto Y, Asai O et al. Cardiac expression of placental growth factor predicts the improvement of chronic phase left ventricular function in patients with acute myocardial infarction. J Am Coll Cardiol 2006; 47: 1559-1567.
25. Selvaraj SK, Giri RK, Perelman N, Johnson C, Malik P, Kalra VK. Mechanism of monocyte activation and expression of proinflammatory cytochemokines by placenta growth factor. Blood 2003; 102: 1515-1524.
26. Jeganathan VS. Anti-angiogenesis drugs in diabetic retinopathy. Curr Pharm Biotechnol 2011; 12: 369-372.
27. Duda DG, Batchelor TT, Willett CG, Jain RK. VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Trends Mol Med 2007; 13: 223-230.
28. Wang Y, Zhou Y, He L, Hong K, Su H, Wu Y et al. Gene delivery of soluble vascular endothelial growth factor receptor-1 (sFlt-1) inhibits intra-plaque angiogenesis and suppresses development of atherosclerotic plaque. Clin Exp Med 2011; 11: 113-121.
29. Luttun A, Tjwa M, Moons L, Wu Y, Ngelillo-Scherrer A, Liao F et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 2002; 8: 831-840.
30. Law LW, Sahota DS, Chan LW, Chen M, Lau TK, Leung TY. Effect of long-term storage on placental growth factor and fms-like tyrosine kinase1 measurements in samples from pregnant women. J Matern Fetal Neonatal Med 2010; 23: 1475-1480.